Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Purinostat mesylate - Chengdu Zenitar Biomedical Technology

Drug Profile

Purinostat mesylate - Chengdu Zenitar Biomedical Technology

Alternative Names: Prilinostat Mesylate - Chengdu Zenitar Biomedical Technology

Latest Information Update: 16 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chengdu Zenitar Biomedical Technology
  • Class Amides; Aniline compounds; Antineoplastics; Mesylates; Methylamines; Morpholines; Purines; Pyrimidines; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
  • Phase I Multiple myeloma
  • No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 03 Jul 2024 Chengdu Zenitar Biomedical Technology plans a phase I/II trial for Multiple myeloma (Second-line therapy or greater) in China (NCT06484829)
  • 31 May 2024 Efficacy and adverse events data from a phase IIa trial in Diffuse large B cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Pharmacodynamics data from preclinical studies in Diffuse large B-cell lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top